Table 1.
Prospective cohort (n = 29) | Validation cohort 1 Bv+/− CT (n = 61) |
Validation cohort 2 CT only (n = 27) |
|
---|---|---|---|
Age (years) | |||
Median | 59.1 | 56.9 | 59.9 |
Range | (32–76) | (31–79) | (37–81) |
Use of glucocorticoids [n (%)] | |||
No | 13 (45%) | 18 (30%) | 13 (48%) |
Yes | 16 (55%) | 43 (70%) | 14 (52%) |
Median survival (months) | |||
OS | 8.5 | 8.0 | 9.0 |
Bv bevacizumab, CT chemotherapy, PFS progression-free survival, OS overall survival